Patients receiving an ENaBL therapy need not undergo removal of immune cells for processing and reinfusion, eliminating the complexity and lengthy turnaround time associated with conventional ...

EsoBiotec’s platform has the potential to eliminate the complex and time-consuming process for manufacturing, helping to make CAR-T cell therapies more accessible.

Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite challenges like cost and access.

After hours: March 17 at 4:05:09 PM EDT Loading Chart for ANGO ...

Shoreline's approach of developing off-the-shelf (allogeneic) cell therapies – which don't require the convoluted and time-consuming harvesting, modification and reinfusion of patient-derived ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Multiple myeloma is part of the spectrum of diseases ranging from MGUS to plasma cell leukemia, and similar to MGUS, is characterized by proliferation of a plasma cell clone and subsequent ...